Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
male and females 40 to 80 years of age (inclusive)
COPD diagnosis
Current or previous smokers with a cigarette smoking history of at least 10 pack-
Post-albuterol FEV1/FVC of 0.70 or less
Post-albuterol FEV1 of 35% to 80% (inclusive)
You may not be if
Pregnant or lactating females
current diagnosis of asthma
respiratory disorders other than COPD
clinically significant cardiovascular, neurological, psychiatric, renal, immunological, endocrine, or hematological abnormalities that are uncontrolled
clinically significant sleep apnea
previous lung resection surgery
clinically significant abnormalities confirmed by chest x-ray that are not related to COPD
hospitalization for COPD within 3 months of screening
use of antibiotics for lower respiratory tract infection within 6 months of screening
abnormal and clinically significant 12-lead ECG findings
current malignancy in remission for less that 5 years
medical conditions that would contraindicate the use of anticholinergics
positive hepatitis B or C test
history of alcohol or drug abuse
unable to withhold albuterol for 6 or more hours
use of long term oxygen therapy
conditions that would limit the validity of informed consent
use of GW642444 or GSK233705 in previous studies
use of an investigation drug with 30 days of screening
use of inhaled corticosteroids (ICS) at a dose greater than 1000mcg of fluticasone propionate or equivalent
hypersensitivity to beta-agonists
concurrent use of long-acting beta-agonists (LABA) or long-acting muscaring antagonists, LABA/ICS combination products, cytochrome p450 inhibitors, oral or depot corticosteroids, theophyllines, oral beta agonists, oral leukotrine modulators, inhaled short acting anticholinergics.
Clareo Health | Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD
